Josef Ozer

3.8k total citations · 2 hit papers
27 papers, 2.5k citations indexed

About

Josef Ozer is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Josef Ozer has authored 27 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in Josef Ozer's work include RNA Research and Splicing (6 papers), Genomics and Chromatin Dynamics (6 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). Josef Ozer is often cited by papers focused on RNA Research and Splicing (6 papers), Genomics and Chromatin Dynamics (6 papers) and Drug-Induced Hepatotoxicity and Protection (4 papers). Josef Ozer collaborates with scholars based in United States, United Kingdom and Switzerland. Josef Ozer's co-authors include Wendy Bailey, Marcia H. Ratner, Martin Shaw, Shelli Schomaker, Paul M. Lieberman, Paul A. Moore, Arthur H. Bolden, Nagaraja Muniappa, Douglas T. Thudium and Daniel Holder and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Genes & Development.

In The Last Decade

Josef Ozer

27 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The current state of serum biomarkers of hepatotoxicity

2007 999 citations Josef Ozer, Marcia H. Ratner et al. Toxicology profile →
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies

2010 520 citations Vishal S. Vaidya, Josef Ozer et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Josef Ozer United States	18	961	442	362	298	248	27	2.5k
Frank J. Burczynski Canada	25	919 1.0×	349 0.8×	126 0.3×	443 1.5×	123 0.5×	96	2.6k
Dong‐Yun Ouyang China	33	1.9k 2.0×	260 0.6×	266 0.7×	391 1.3×	189 0.8×	82	2.8k
Yoshihisa Tomioka Japan	26	1.4k 1.4×	139 0.3×	257 0.7×	175 0.6×	192 0.8×	107	2.7k
Masao Miwa Japan	32	878 0.9×	434 1.0×	80 0.2×	306 1.0×	135 0.5×	83	2.7k
Jing Gong China	31	1.0k 1.1×	186 0.4×	137 0.4×	302 1.0×	158 0.6×	101	2.9k
Graham R. Betton United Kingdom	15	583 0.6×	501 1.1×	119 0.3×	124 0.4×	254 1.0×	34	2.2k
Rui‐Chao Lin China	33	2.1k 2.2×	623 1.4×	309 0.9×	247 0.8×	563 2.3×	72	3.3k
Junya Nagai Japan	28	824 0.9×	419 0.9×	183 0.5×	143 0.5×	79 0.3×	88	2.6k
Jean‐Charles Gautier France	27	852 0.9×	1.2k 2.8×	192 0.5×	133 0.4×	119 0.5×	60	2.8k

Countries citing papers authored by Josef Ozer

Since Specialization

Citations

This map shows the geographic impact of Josef Ozer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Josef Ozer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Josef Ozer more than expected).

Fields of papers citing papers by Josef Ozer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Josef Ozer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Josef Ozer. The network helps show where Josef Ozer may publish in the future.

Co-authorship network of co-authors of Josef Ozer

This figure shows the co-authorship network connecting the top 25 collaborators of Josef Ozer. A scholar is included among the top collaborators of Josef Ozer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Josef Ozer. Josef Ozer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ratner, Marcia H., David H. Farb, Josef Ozer, Robert G. Feldman, & Raymon Durso. (2014). Younger age at onset of sporadic Parkinson’s disease among subjects occupationally exposed to metals and pesticides. Interdisciplinary Toxicology. 7(3). 123–133. 30 indexed citations

Brodfuehrer, Joanne, Andrew L. Rankin, Jason Edmonds, et al.. (2013). Quantitative Analysis of Target Coverage and Germinal Center Response by a CXCL13 Neutralizing Antibody in a T-Dependent Mouse Immunization Model. Pharmaceutical Research. 31(3). 635–648. 17 indexed citations

Ozer, Josef, Anne Lanevschi, Ina Schuppe‐Koistinen, et al.. (2010). A Systematic Approach to Preclinical and Clinical Safety Biomarker Qualification Incorporating Bradford Hill's Principles of Causality Association. Clinical Pharmacology & Therapeutics. 88(2). 260–262. 7 indexed citations

Vaidya, Vishal S., Josef Ozer, Frank Dieterle, et al.. (2010). Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nature Biotechnology. 28(5). 478–485. 520 indexed citations breakdown →

Yu, Yan, Hong Jin, Daniel Holder, et al.. (2010). Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nature Biotechnology. 28(5). 470–477. 147 indexed citations

Palandra, Joe, et al.. (2009). Endogenous ethanolamide analysis in human plasma using HPLC tandem MS with electrospray ionization. Journal of Chromatography B. 877(22). 2052–2060. 39 indexed citations

Ozer, Josef. (2009). A guidance for renal biomarker lead optimization and use in translational pharmacodynamics. Drug Discovery Today. 15(3-4). 142–147. 8 indexed citations

Ozer, Josef, J. Gerry Kenna, Joe Palandra, et al.. (2009). Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regulatory Toxicology and Pharmacology. 56(3). 237–246. 58 indexed citations

Ozer, Josef, Marcia H. Ratner, Martin Shaw, Wendy Bailey, & Shelli Schomaker. (2007). The current state of serum biomarkers of hepatotoxicity. Toxicology. 245(3). 194–205. 999 indexed citations breakdown →

10.

Saha, Shamol, Michael Buratovich, Heath D. Schmidt, et al.. (2006). Transcription Factor IIA τ Is Associated with Undifferentiated Cells and Its Gene Expression Is Repressed in Primary Neurons at the Chromatin Level In Vivo. Stem Cells and Development. 15(2). 175–190. 3 indexed citations

11.

Ivanov, Gleb S., et al.. (2003). Sp and GATA factors are critical for Apolipoprotein AI downstream enhancer activity in human HepG2 cells. Gene. 323. 31–42. 4 indexed citations

12.

Ozer, Josef, Paul A. Moore, & Paul M. Lieberman. (2000). A Testis-specific Transcription Factor IIA (TFIIAτ) Stimulates TATA-binding Protein-DNA Binding and Transcription Activation. Journal of Biological Chemistry. 275(1). 122–128. 49 indexed citations

13.

Moore, Paul A., Josef Ozer, Gwénaël Jan, et al.. (1999). A Human TATA Binding Protein-Related Protein with Altered DNA Binding Specificity Inhibits Transcription from Multiple Promoters and Activators. Molecular and Cellular Biology. 19(11). 7610–7620. 82 indexed citations

14.

Ozer, Josef, Katherine Mitsouras, Dennis Zerby, Michael Carey, & Paul M. Lieberman. (1998). Transcription Factor IIA Derepresses TATA-binding Protein (TBP)-associated Factor Inhibition of TBP-DNA Binding. Journal of Biological Chemistry. 273(23). 14293–14300. 50 indexed citations

15.

Kim, Arianna L., Maureen Maher, Josef Ozer, et al.. (1997). An Imperfect Correlation between DNA Replication Activity of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1) and Binding to the Nuclear Import Receptor, Rch1/importin α. Virology. 239(2). 340–351. 36 indexed citations

16.

Ozer, Josef, Arthur H. Bolden, & Paul M. Lieberman. (1996). Transcription Factor IIA Mutations Show Activator-specific Defects and Reveal a IIA Function Distinct from Stimulation of TBP-DNA Binding. Journal of Biological Chemistry. 271(19). 11182–11190. 46 indexed citations

17.

Ginsburg, Geoffrey S., Josef Ozer, & S K Karathanasis. (1995). Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4.. Journal of Clinical Investigation. 96(1). 528–538. 54 indexed citations

18.

Ozer, Josef, et al.. (1994). The human myeloid cell nuclear differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q that are expressed specifically in hematopoietic cells. Blood. 83(8). 2153–2162. 45 indexed citations

19.

Ozer, Josef, Roger Chalkley, & Linda Sealy. (1993). Isolation of the CCAAT transcription factor subunit EFIA cDNA and a potentially functional EFIA processed pseudogene from Bos taurus: insights into the evolution of the EFIA/dbpB/YB-1 gene family. Gene. 124(2). 223–230. 14 indexed citations

20.

Ozer, Josef, Roger Chalkley, & Linda Sealy. (1993). Characterization of rat pseudogenes for enhancer factor I subunit A: ripping provides clues to the evolution of the EFIAdbpB/YB-1 multigene family. Gene. 133(2). 187–195. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact